Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Nov;35(11):3282-3286.
doi: 10.1038/s41375-021-01232-2. Epub 2021 Apr 8.

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

Francesco Paolo Tambaro  1   2 , Harjeet Singh  1 , Emily Jones  3 , Michael Rytting  1 , Kris M Mahadeo  1 , Philip Thompson  3 , Naval Daver  3 , Courtney DiNardo  3 , Tapan Kadia  3 , Guillermo Garcia-Manero  3 , Tim Chan  4 , Rutul R Shah  4 , William G Wierda  5
Affiliations
Clinical Trial

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

Francesco Paolo Tambaro et al. Leukemia. 2021 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

FPT: No relevant conflicts of interest to report. HS: Research funding from Precigen/Intrexon. EJ: No relevant conflicts of interest to report. MR: No relevant conflicts of interest to report. KM: No relevant conflicts of interest to report. PT: No relevant conflicts of interest to report. ND: No relevant conflicts of interest to report. CD: No relevant conflicts of interest to report. TK: No relevant conflicts of interest to report. GGM: No relevant conflicts of interest to report. TC: Employee of Precigen/Intrexon. RRS: Employee of Precigen/Intrexon. WGW: No relevant conflicts of interest to report.

References

    1. Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol. 2018. 10.1002/ajh.25162. - PMC - PubMed
    1. Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018;132:598–607. doi: 10.1182/blood-2018-01-821629. - DOI - PMC - PubMed
    1. DiNardo CD. Ivosidenib in IDH1-mutated acute myeloid leukemia. N. Engl J Med. 2018;379:1186. doi: 10.1056/NEJMc1809507. - DOI - PubMed
    1. Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–31. doi: 10.1182/blood-2017-04-779405. - DOI - PMC - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44. doi: 10.1056/NEJMoa1707447. - DOI - PMC - PubMed

Publication types

MeSH terms